PEPTIDEREPORT

Video claim watch

Are Peptides Safe? What You Need to Know About BPC-157, TB-500 & Their Unknown Risks

A high-production interview built around unknown risks gives the video rail a broader safety lens beyond single-compound benefit claims.

The Proof with Simon Hill channel46:18 runtime8.5K views when checked

Published Apr 21, 2026. Metadata checked Jul 10, 2026.

Watch on YouTube

Transcript review

6 material claims logged

Published with source gaps audit stateauto-captioned transcript0 operational-guidance flags3 source gaps

Reviewed Jul 12, 2026. Next review Aug 12, 2026.

high-value drug-development and risk framing.

auto-caption available; 11 creator chapters.

Claim-by-claim audit

What the video says, and what needs checking

00:07:14
Regulatory context

Explains that drug candidates must pass preclinical work and phased human trials and that most candidates fail.

Review topic: drug-development evidence.

Checked against: Primary-source record still needed

FDA drug-development materials; do not substitute this statistic for a compound-specific assessment.

00:22:32
High-risk safety claim

Identifies cell proliferation and angiogenesis as biological pathways that can overlap with cancer biology, without claiming these peptides cause cancer.

Review topic: BPC-157 / TB-500 / tumor uncertainty.

Checked against: FDA BPC-157 compounding safety risk: immunogenicity

00:25:06
High-risk mechanism claim

Notes that BPC-157 and TB-500 fragments are not necessarily identical to naturally produced parent molecules.

Review topic: naturalness claims.

Checked against: Primary-source record still needed

compound-specific structural records.

00:36:09
Regulatory contextCommercial context

Rejects the claim that lack of FDA approval proves protection of “big pharma”; emphasizes absence of submitted clinical evidence.

Review topic: regulatory narrative.

Checked against: Primary-source record still needed

ClinicalTrials.gov and FDA records.

Connected research

Compounds discussed

BPC-157 BPC-157 is an experimental peptide with extensive animal research but very limited human evidence. A Phase 1 registry record has no posted efficacy result, and a small uncontrolled knee-pain report does not establish benefit. It is not FDA-approved and is prohibited in sport. TB-500 TB-500 is marketed as a thymosin-beta-4-related recovery peptide. The sources currently linked to this profile are regulatory records, not human efficacy studies. It is not FDA-approved and was scheduled for FDA advisory committee discussion in July 2026. CJC-1295 (with DAC) CJC-1295 with DAC is a synthetic GHRH analog developed by ConjuChem using drug affinity complex (DAC) technology to bind albumin and extend half-life to 6-8 days. It is not FDA-approved; ConjuChem discontinued clinical development. A separate profile covers CJC-1295 without DAC (Mod GRF 1-29), the short-acting form commonly stacked with ipamorelin. Ipamorelin Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that stimulates GH release via ghrelin receptor agonism. It is not FDA-approved for any indication and has limited published human clinical data. It is widely discussed in online fitness and anti-aging communities, often marketed as the 'safest' GHS due to its selectivity for GH release over cortisol and prolactin.

Source check

Records used in this claim audit